Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $131 | $84 | $66 | $60 |
| - Cash | $0 | $1 | $1 | $2 |
| + Debt | $11 | $9 | $9 | $9 |
| Enterprise Value | $142 | $93 | $75 | $68 |
| Revenue | $17 | $14 | $13 | $12 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Gross Profit | $10 | $9 | $8 | $7 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| EBITDA | $4 | $3 | $3 | $3 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |
| Net Income | $2 | $2 | $1 | $1 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| % Growth | 16.5% | 140.6% | -35.1% | – |
| Operating Cash Flow | $3 | $3 | $2 | $2 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $3 | $2 | $1 | $1 |